Fighting restenosis after coronary angioplasty: Contemporary and future treatment options

International Journal of Cardiology

Volumn 83, Issue 3, 2002, Pages 199-205

  Horlitz, Marc ^a   Sigwart, Ulrich ^b   Niebauer, Josef ^c  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Angioplasty; Gene therapy; Restenosis; Statins

Indexed keywords

ARGININE; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; PROBUCOL; SIMVASTATIN; STATIN; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM; GENE THERAPY; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OXIDATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; STENTS;

EID: 0036261662     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00033-5     Document Type: Review

References (41)

1. Percutaneous transluminal coronary angioplasty
2. Prevention of restenosis after coronary balloon angioplasty: Rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial
3. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty
4. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. (The STRESS trial)
5. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. (The Benestent study)
6. Interim analysis of the Benestent trial (abstract)
7. Multizentrische Ergebnisse der koronaren Implantation von Ballon expandierbaren Palmaz-Schatz-Gefäß-Stützen
8. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia
9. Restenosis after successful percutaneous transluminal coronary angioplasty: The Montreal Heart Institute experience
10. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia
11. Molekulare und zelluläre Mechanismen der Arteriosklerose und Restenose: M.öglichkeiten der Gentherpie
12. Restenosis after coronary angioplasty: An overview
13. Prevention of restenosis after percutaneous transluminal coronary angioplasty: The search for a 'magic bullet'
14. Prevention of restenosis by lovastatin after successful coronary angioplasty
15. The evolving role of statins in the management of atherosclerosis
16. Lovastatin reduces myointimal proliferation after vascular injury (abstract)
17. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit
18. HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolaemic rabbits
19. ML-236A, ML-236B, ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
20. Current and future treatment of hyperlipidemia: The role of statins
21. Statins do more than just lower cholesterol
22. Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis
23. Current perspectives on statins
24. Long-term effects of pravastatin on plasma concentration of C-reactive protein
25. For the cholersterol and recurrent events trial investigators
26. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
27. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Study (4S)
28. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
29. Background and methods for the Lovastatin restenosis trial after percutaneous transluminal coronary angioplasty
30. Lovastatin Restenosis trial: Final results (abstract)
31. Lack of effect of lovastatin on restenosis after coronary angioplasty
32. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty
33. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty
34. The effect of pravastatin on prevention of restenosis after successful percutaneous coronary angioplasty
35. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty. Final results of the fluvastatin angiographic restenosis (FLARE) trial
36. Effect of statin therapy on restenosis after coronary stent implantation
37. Gene transfer of nitric oxide synthase. Effects on endothelial biology
38. A pressure-mediated non-viral method for efficient arterial gene and oligonucleotide transfer
39. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
40. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits
41. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty